CLINAM 9 / 2016 Conference and Exhibition
European & Global Summit for Cutting-Edge Medicine
June 26 – 29, 2016
Clinical Nanomedicine and Targeted Medicine
Enabling Technologies for Personalized Medicine
Conference Venue: Congress Center, Messeplatz 21, 4058 Basel,
Organizers Office: CLINAM‐Foundation, Alemannengasse 12, P.B. 4016 Basel
• Prof. Dr.med.PatrickHunziker, University Hospital Basel (CH) (Chairman)
• Prof. Dr.med. ChristophAlexiou, UniversityHospitalErlangen(D)
• Prof. Dr. Lajos Balogh, Editor-in-Chief Nanomedicine, Nanotechnology in Biology and Medicine, Elsevier and Member of the Executive Board, American Society for Nanomedicine, Boston (USA)
• Prof. Dr. GerdBinnig, Nobel Laureate, Munich(D)
• Prof. Dr. Yechezkel Barenholz, HebrewUniversity, Hadassah Medical School, Jerusalem(IL)
• Prof. Dr. med. Omid Farokhzad, Associate Professor and Director of Laboratory of Nanomedicine and Biomaterials, Harvard Medical School and Brigham and Women's Hospital; Founder of BIND Therapeutics, Biosciences and Blend Therapeutics, Cambridge, Boston (USA)
• Prof. Dr. med. Dong Soo Lee, PhD. Chairman Department of Nuclear Medicine Seoul National University Seoul, (KOR)
• Dr. med. h.c. Beat Löffler, MA, European Foundation for Clinical Nanomedicine, Basel (CH)
• Prof. Dr. Jan Mollenhauer, Lundbeckfonden Centerof Excellence NanoCAN, Universityof Southern Denmark, Odense (DK)
• Prof. Dr. med. Marisa Papaluca Amati, European Medicines Agency, London (UK).
• Prof. Dr. GertStorm, Institutefor Pharmaceutical Sciences, Utrecht University, (NL)
• Prof. Dr. Viola Vogel, Laboratory for Biologically Oriented Materials, ETH, Zürich (CH)
The Conference at a Glance
In the previous eight years, the CLINAM Summit grew to the largest in its field with 12 presenting Noble Laureates and more than 500 participants from academia, industry, regulatory authorities and policy from over 40 different countries in Europe and worldwide. With this success and broad support by well beyond 20 renowned collaborating initiatives, the CLINAM-Summit is today one of the most important marketplaces for scientific exchange and discussions of regulatory, political and ethical aspects in this field of cutting-edge medicine.
In particular, the CLINAM Summit emerged as exquisite forum for translation from bench to bedside for European and international networking, for industrial collaboration between companies, with academia, and as point-of-contact with customers. The summit is presently the only place to meet the regulatory authorities from all continents to debate the needs of all stakeholders in the field with the legislators.
CLINAM 9/2016 continues with its successful tradition to cover the manifold interdisciplinary fields of Clinical and Targeted Nanomedicine in major and neglected diseases. As special focus area, CLINAM 09/2016 adds translation and enabling technologies, including, for example, cutting-edge molecular profiling, nano-scale analytics, single cell analysis, stem cell technologies, tissue engineering, in and ex vivo systems as well as in vitro substitute systems for efficacy and toxicity testing.
CLINAM 09/2016 covers the entire interdisciplinary spectrum of Nanomedicine and Targeted Medicine from new materials with potential medical applications and enabling technologies over diagnostic and therapeutic translation to clinical applications in infectious, inflammatory and neurodegenerative diseases, as well as diabetes, cancer and regenerative medicine to societal implications, strategical issues, and regulatory affairs. The conference is sub-divided into three different tracks running in parallel and provides ample possibilities for exhibitors as indicated by steadily increasing requests.
The Tracks of the Summit
Track 1: Clinical and Targeted Nanomedicine – Basic Research • Disease Mechanisms and Personalized Medicine
• Regenerative Medicine • Novel Therapeutic and Diagnostic Approaches • Active and Passive Targeting • Targeted Delivery (antibodies, affibodies, aptamers, and nano drug delivery devices) • Accurin Technology •Nano-Toxicology
Track 2: Clinical and Targeted Nanomedicine: Translation • Unsolved Medical Problems • Personalized Medicine and Theranostic Approaches • Regenerative Medicine • Advanced Breaking and Ongoing Clinical Trials • Applied Nanomedical Diagnostics and Therapeutics
Track 3: Enabling Technologies • Nanomaterial Analytics and Testing • Molecular Profiling for Research and Efficacy/Toxicology Testing (Genomics, Proteomics, Glycomics, Lipidomics, Metabolomics) • Functional Testing Assays and Platforms• Single Cell Analyses • Cell Tracking • Stem Cell Biology and Engineering Technologies
Microfluidics • Tissue Engineering – Tissues-on-a-Chip-Bioprinting • In vivo Testing • Novel Imaging Approaches
• Medical Devices
Track 4: Regulatory, Societal Affairs and Networking • Regulatory Issues in Nanomedicine • Strategy and Policy
• The Patients` Perspective • Ethical Issues in Nanomedicine • University Village • Cutting-Edge EU-Project Presentations • Networking for International Consortium Formation • Regulatory Authorities Sessions
Based on last year’s exhibition it is expected to have about 30 Exhibitors at this Summit. Exhibitors can profit of the possibility to meet their target visitors on 1 single spot in Basel at CLINAM 9 / 2016. With its concept for the exhibition, the international CLINAM Summit becomes also the place for the pulse of the market and early sales in the field of cutting-edge medicine.
Call for Papers
Deadline April 25, 2016 for oral Presentations Deadline for “Poster Only” Submission is May 15, 2016. Later submitted Posters can still be accepted but will not be included in the Summit-Proceedings. (See instruction in Folder on Page 25).
Sponsons of CLINAM
Registration Fees (For Exhibition Pricing Look Folder, Page 25)
The European Foundation for Clinical Nanomedicine is a non-profit institution aiming at advancing medicine to the benefit of individuals and society through the application of nanoscience. Aiming at prevention, diagnosis, and therapy through nanomedicine as well as at exploration of its implications, the Foundation reaches its goals through support of clinically focussed research and of interaction and information flow between clinicians, researchers, the public, and other stakeholders. The recognition of the large future impact of nanoscience on medicine and the observed rapid advance of medical applications of nanoscience have been the main reasons for the creation of the Foundation.
Nanotechnology for Medicine
Nanotechnology is generally considered as the key technology of the 21st century. It is an interdisciplinary scientific field focusing on methods, materials, and tools on the nanometer scale, i.e. one millionth of a millimeter. The application of this science to medicine seeks to benefit patients by providing prevention, early diagnosis, and effective treatment for prevalent, for disabling, and for currently incurable medical conditions.